GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (OTCPK:RTNXF) » Definitions » LT-Debt-to-Total-Asset

RTNXF (Renalytix) LT-Debt-to-Total-Asset : 0.86 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Renalytix LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Renalytix's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.86.

Renalytix's long-term debt to total assets ratio increased from Sep. 2023 (0.30) to Sep. 2024 (0.86). It may suggest that Renalytix is progressively becoming more dependent on debt to grow their business.


Renalytix LT-Debt-to-Total-Asset Historical Data

The historical data trend for Renalytix's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix LT-Debt-to-Total-Asset Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.01 - 0.15 0.25 0.54

Renalytix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.24 0.56 0.54 0.86

Renalytix LT-Debt-to-Total-Asset Calculation

Renalytix's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )/Total Assets (A: Jun. 2024 )
=4.331/7.972
=0.54

Renalytix's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=4.1/4.794
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix  (OTCPK:RTNXF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Renalytix LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Renalytix's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix Business Description

Traded in Other Exchanges
Address
2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.